Citation Impact
Citing Papers
2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
2017 Standout
Can Patients at Elevated Risk of Stroke Treated With Anticoagulants Be Further Risk Stratified?
2007
Effect of Clopidogrel Added to Aspirin in Patients with Atrial Fibrillation
2009 Standout
Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack
2014 Standout
2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease
2014 Standout
Randomized Trial of Genotype-Guided Versus Standard Warfarin Dosing in Patients Initiating Oral Anticoagulation
2007
2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: Executive Summary
2014 Standout
2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary
2014 Standout
Edoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism
2013 Standout
Antithrombotic Therapy for Venous Thromboembolic Disease
2008 Standout
Risk score to predict serious bleeding in stable outpatients with or at risk of atherothrombosis
2010
Pharmacology and Management of the Vitamin K Antagonists
2008 Standout
Predictive variables for major bleeding events in patients presenting with documented acute venous thromboembolism. Findings from the RIETE Registry
2008
Bleeding with anticoagulation therapy – Who is at risk, and how best to identify such patients
2009
Pharmacodynamic resistance to warfarin associated with a Val66Met substitution in vitamin K epoxide reductase complex subunit 1
2004
A Novel User-Friendly Score (HAS-BLED) To Assess 1-Year Risk of Major Bleeding in Patients With Atrial Fibrillation
2010 Standout
Evidence-Based Management of Anticoagulant Therapy
2012
Warfarin Maintenance Dosing Patterns in Clinical Practice
2005
VKORC1 haplotypes and their impact on the inter-individual and inter-ethnical variability of oral anticoagulation
2005
Refining Clinical Risk Stratification for Predicting Stroke and Thromboembolism in Atrial Fibrillation Using a Novel Risk Factor-Based Approach
2009 Standout
The predictive ability of bleeding risk stratification models in very old patients on vitamin K antagonist treatment for venous thromboembolism: results of the prospective collaborative EPICA study
2013
Oral Anticoagulant Therapy
2012 Standout
Antithrombotic Therapy for VTE Disease
2016 Standout
Guideline-adherent antithrombotic treatment is associated with improved outcomes compared with undertreatment in high-risk patients with atrial fibrillation. The Euro Heart Survey on Atrial Fibrillation
2007
Emergency Hospitalizations for Adverse Drug Events in Older Americans
2011 Standout
The Influence of Patient Adherence on Anticoagulation Control With Warfarin
2007
Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
2009 Standout
A Prospective Natural-History Study of Coronary Atherosclerosis
2011 Standout
Comparative Validation of a Novel Risk Score for Predicting Bleeding Risk in Anticoagulated Patients With Atrial Fibrillation
2010
Effect of VKORC1 Haplotypes on Transcriptional Regulation and Warfarin Dose
2005
Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials
2013 Standout
Pulmonary embolism and deep vein thrombosis
2012
Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism
2009 Standout
Antithrombotic Therapy for VTE Disease
2012 Standout
GRADE guidelines: 3. Rating the quality of evidence
2011 Standout
CYP2C9 Genotype-guided Warfarin Prescribing Enhances the Efficacy and Safety of Anticoagulation: A Prospective Randomized Controlled Study
2007
Interaction of Warfarin With Drugs, Natural Substances, and Foods
2005
The Missing Diversity in Human Genetic Studies
2019 Standout
Outcomes of Oral Anticoagulant Therapy Managed by Telephone vs In-Office Visits in an Anticoagulation Clinic Setting
2006
Factors Affecting Quality of Anticoagulation Control Among Patients With Atrial Fibrillation on Warfarin
2013
Dabigatran versus Warfarin in Patients with Atrial Fibrillation
2009 Standout
Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations
2018 Standout
10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes
2008 Standout
Health literacy and anticoagulation-related outcomes among patients taking warfarin
2006
Antithrombotic Therapy in the Elderly
2010
Risk factors for nonadherence to warfarin: results from the IN‐RANGE study
2008
Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO)
2011
Effect of Study Setting on Anticoagulation Control
2006
Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Hip Arthroplasty
2008 Standout
Prevention and treatment of bleeding complications in patients receiving vitamin K antagonists, Part 1: Prevention
2009
The HAS-BLED Score Identifies Patients with Acute Venous Thromboembolism at High Risk of Major Bleeding Complications during the First Six Months of Anticoagulant Treatment
2015
Reinitiation of Anticoagulation After Warfarin-Associated Intracranial Hemorrhage and Mortality Risk: The Best Practice for Reinitiating Anticoagulation Therapy After Intracranial Bleeding (BRAIN) Study
2011
A novel risk prediction score in atrial fibrillation for a net clinical outcome from the ENGAGE AF-TIMI 48 randomized clinical trial
2016
Bleeding risk in ‘real world’ patients with atrial fibrillation: comparison of two established bleeding prediction schemes in a nationwide cohort
2011
The Pharmacology and Management of the Vitamin K Antagonists
2004 Standout
Hemorrhagic Complications of Anticoagulant and Thrombolytic Treatment
2008
Prosthetic Heart Valve Thrombosis
2016
Influence of CYP2C9 and VKORC1 on warfarin response during initiation of therapy
2009
Predictable and Less Predictable Unwanted Cardiac Drugs Effects: Individual Pre‐Disposition and Transient Precipitating Factors
2010
A New Risk Scheme to Predict Warfarin-Associated Hemorrhage
2011
Influence of CYP2C9 genotype on warfarin dose requirements—a systematic review and meta-analysis
2008
Main haplotypes and mutational analysis of vitamin K epoxide reductase (VKORC1) in a Swedish population: a retrospective analysis of case records
2006 StandoutNobel
Antithrombotic Therapy for Atrial Fibrillation
2012
Clinical performance of bleeding risk scores for predicting major and clinically relevant non‐major bleeding events in patients receiving warfarin
2013
CYP2C9 polymorphism and warfarin sensitivity in Taiwan Chinese
2006
Oral Apixaban for the Treatment of Acute Venous Thromboembolism
2013 Standout
Prospective, multicenter validation of prediction scores for major bleeding in elderly patients with venous thromboembolism
2012
Standardized Bleeding Definitions for Cardiovascular Clinical Trials
2011 Standout
Guidelines for the Early Management of Patients With Acute Ischemic Stroke
2013 Standout
Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism
2017 Standout
2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation
2014 Standout
Evaluation and Management of Chronic Kidney Disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2012 Clinical Practice Guideline
2013 Standout
Influence of CYP2C9 and VKORC1 on Warfarin Dose, Anticoagulation Attainment and Maintenance Among European–Americans and African–Americans
2008
Should Atrial Fibrillation Patients With Only 1 Nongender-Related CHA 2 DS 2 -VASc Risk Factor Be Anticoagulated?
2016
Pharmacogenetic differences between warfarin, acenocoumarol and phenprocoumon
2008
Selecting Patients With Atrial Fibrillation for Anticoagulation
2004
Oral Rivaroxaban for Symptomatic Venous Thromboembolism
2010 Standout
The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen
2005
Decision aids for people facing health treatment or screening decisions
2017 Standout
2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons
2019 Standout
Management of Massive and Submassive Pulmonary Embolism, Iliofemoral Deep Vein Thrombosis, and Chronic Thromboembolic Pulmonary Hypertension
2011 Standout
The impact of bleeding complications in patients receiving target-specific oral anticoagulants: a systematic review and meta-analysis
2014
ACC/AHA 2006 Guidelines for the Management of Patients With Valvular Heart Disease
2006 Standout
Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation
2007 Standout
Estimation of the Warfarin Dose with Clinical and Pharmacogenetic Data
2009
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics‐Guided Warfarin Dosing: 2017 Update
2017
Worldwide Epidemiology of Atrial Fibrillation
2013 Standout
Low Health Literacy and Health Outcomes: An Updated Systematic Review
2011 Standout
Minimizing the Risks of Anticoagulants and Platelet Inhibitors
2010
2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
2020 Standout
2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation
2014 Standout
Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism
2012 Standout
COVID-19 and its implications for thrombosis and anticoagulation
2020 Standout
The risk of bleeding with warfarin: A systematic review and performance analysis of clinical prediction rules
2007
2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation
2015 Standout
Use and Effectiveness of Warfarin in Medicare Beneficiaries With Atrial Fibrillation
2006
Use of the CHA 2 DS 2 -VASc and HAS-BLED Scores to Aid Decision Making for Thromboprophylaxis in Nonvalvular Atrial Fibrillation
2012
A Pilot Randomized Controlled Trial of a Decision Support Tool to Improve the Quality of Communication and Decision‐Making in Individuals with Atrial Fibrillation
2012
Randomized, Controlled Trial of Ultrasound-Assisted Catheter-Directed Thrombolysis for Acute Intermediate-Risk Pulmonary Embolism
2013 Standout
Prevention of stroke in patients with atrial fibrillation: current strategies and future directions
2008
2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes
2014 Standout
Works of Paul E. Milligan being referenced
Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin
2003
Laboratory and clinical outcomes of pharmacogenetic vs. clinical protocols for warfarin initiation in orthopedic patients
2008
Prospective dosing of warfarin based on cytochrome P-450 2C9 genotype
2005
Warfarin Dose Reduction vs Watchful Waiting for Mild Elevations in the International Normalized Ratio*
2003
Use of Pharmacogenetic and Clinical Factors to Predict the Therapeutic Dose of Warfarin
2008
Ability of VKORC1 and CYP2C9 to predict therapeutic warfarin dose during the initial weeks of therapy
2009
Patient and physician satisfaction with a telephone-based anticoagulation service
2001
Pharmacology and pharmacogenetics of warfarin and other coumarins when used with supplements
2005
Efficacy and safety of high-dose thromboprophylaxis in morbidly obese inpatients
2013
Clinical classification schemes for predicting hemorrhage: Results from the National Registry of Atrial Fibrillation (NRAF)
2006
Substitution of Generic Warfarin for Coumadin in an HMO Setting
2002
Establishing and running an effective telephone-based anticoagulation service
2001
Effect of warfarin nonadherence on control of the International Normalized Ratio
2004
Risk factors for bleeding in patients taking coumarins.
2002
Genetic-based dosing in orthopedic patients beginning warfarin therapy
2007